Clinical Trial Update: ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week [Phase 4]

View source ↗

Summary

This Phase 4 trial (ROSPA) assessing patient satisfaction with Actonel 35 mg once weekly in osteoporosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Actonel (risedronate)

Snippet

Sponsor: Sanofi | Conditions: Osteoporosis | Phase 4 | Status: TERMINATED